Q3 EPS Estimates for 10x Genomics Increased by Analyst

Key Points

• Analysts at Leerink Partnrs have revised their Q3 2025 earnings per share (EPS) estimate for 10x Genomics to ($0.26), an improvement from a previous forecast of ($0.28).
• 10x Genomics reported a quarterly revenue of $172.91 million, surpassing the consensus estimate of $139.36 million, with a notable year-over-year revenue growth of 12.9%.
• Institutional investors hold 84.68% of 10x Genomics' stock, indicating significant confidence in the company's future performance.

10x Genomics (NASDAQ:TXG - Free Report) - Equities research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for 10x Genomics in a research note issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.28). The consensus estimate for 10x Genomics' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics' Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.57) EPS.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. The company's revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS.

Several other research firms also recently commented on TXG. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a "hold" rating in a report on Friday, August 8th. Barclays reissued an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. UBS Group boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Bank of America boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Finally, Piper Sandler started coverage on shares of 10x Genomics in a report on Thursday, September 11th. They issued a "neutral" rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $13.65.

10x Genomics Stock Performance

TXG stock opened at $11.89 on Thursday. 10x Genomics has a one year low of $6.78 and a one year high of $18.21. The company's fifty day moving average price is $12.89 and its 200-day moving average price is $11.10. The company has a market capitalization of $1.48 billion, a PE ratio of -16.99 and a beta of 2.05.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Taich sold 22,315 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock valued at $539,865 over the last 90 days. 9.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 10x Genomics

Several hedge funds and other institutional investors have recently made changes to their positions in TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock valued at $62,016,000 after acquiring an additional 4,987,195 shares during the period. Millennium Management LLC raised its stake in shares of 10x Genomics by 434.5% in the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock valued at $46,946,000 after acquiring an additional 4,371,327 shares during the period. AQR Capital Management LLC raised its stake in shares of 10x Genomics by 241.3% in the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock valued at $47,916,000 after acquiring an additional 2,925,372 shares during the period. Quantinno Capital Management LP raised its stake in shares of 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock valued at $25,864,000 after acquiring an additional 1,506,530 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of 10x Genomics by 3,619.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company's stock valued at $10,185,000 after acquiring an additional 1,135,356 shares during the period. Hedge funds and other institutional investors own 84.68% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.